Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

STROKE, SECOND MOST DEADLIEST DISEASE

A stroke occurs when an artery in your brain is blocked or leaks. This causes the oxygen-deprived brain cells to begin dying within minutes. During a stroke, you feel sudden numbness and confusion or have trouble walking and seeing. If left untreated, a stroke can cause long-term disability.

https://www.healthline.com/health/top-10-deadliest-diseases

An IV injection of recombinant tissue plasminogen activator (tPA) — also called alteplase (Activase) — is the gold standard treatment for ischemic stroke. An injection of tPA is usually given through a vein in the arm with the first three hours. Sometimes, tPA can be given up to 4.5 hours after stroke symptoms started.

https://www.mayoclinic.org/diseases-conditions/stroke/diagnosis-treatment/drc-20350119

The cerebral protein levels of VEGF and VEGF expression in the SVZ were also enhanced in VIP-treated rats at 7 days after stroke. VIP treatment obviously increased the number of BrdU positive endothelial cells in the SVZ and density of cerebral microvessels in the ischemic boundary at 28 days after ischemia. Our study suggests that in the ischemic rat brain VIP reduces brain damage and promotes neurogenesis by increasing VEGF. VIP-enhanced neurogenesis is associated with angiogenesis. These changes may contribute to improvement in functional outcome.

https://europepmc.org/article/med/26363093

Stroke Management Market size valued at USD 30.1 billion in 2019 and is expected to witness 6.3% CAGR from 2020 to 2026.

https://www.gminsights.com/industry-analysis/stroke-management-market